JP2007504260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504260A5 JP2007504260A5 JP2006525712A JP2006525712A JP2007504260A5 JP 2007504260 A5 JP2007504260 A5 JP 2007504260A5 JP 2006525712 A JP2006525712 A JP 2006525712A JP 2006525712 A JP2006525712 A JP 2006525712A JP 2007504260 A5 JP2007504260 A5 JP 2007504260A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- interferon
- treatment
- liver diseases
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000015181 infectious disease Diseases 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0320638.0A GB0320638D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
| GB0320638.0 | 2003-09-03 | ||
| PCT/EP2004/009804 WO2005021028A1 (en) | 2003-09-03 | 2004-09-02 | Use of modified cyclosporins for the treatment of hcv disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007504260A JP2007504260A (ja) | 2007-03-01 |
| JP2007504260A5 true JP2007504260A5 (enExample) | 2007-10-11 |
| JP4688806B2 JP4688806B2 (ja) | 2011-05-25 |
Family
ID=28686843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525712A Expired - Fee Related JP4688806B2 (ja) | 2003-09-03 | 2004-09-02 | Ｈｃｖ障害の処置のための修飾シクロスポリンの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7968518B2 (enExample) |
| EP (2) | EP1797892B1 (enExample) |
| JP (1) | JP4688806B2 (enExample) |
| KR (1) | KR101116968B1 (enExample) |
| CN (1) | CN1842343A (enExample) |
| AU (2) | AU2004268382A1 (enExample) |
| BR (1) | BRPI0414062B8 (enExample) |
| CA (1) | CA2537137C (enExample) |
| CY (1) | CY1110506T1 (enExample) |
| DE (1) | DE602004022061D1 (enExample) |
| DK (1) | DK1663287T3 (enExample) |
| ES (1) | ES2328361T3 (enExample) |
| GB (1) | GB0320638D0 (enExample) |
| HR (1) | HRP20090535T1 (enExample) |
| IL (1) | IL173909A (enExample) |
| IS (1) | IS2917B (enExample) |
| MA (1) | MA28032A1 (enExample) |
| MX (1) | MXPA06002394A (enExample) |
| NO (1) | NO20061479L (enExample) |
| NZ (1) | NZ545495A (enExample) |
| PL (1) | PL1663287T3 (enExample) |
| PT (1) | PT1663287E (enExample) |
| RU (1) | RU2389501C2 (enExample) |
| SG (1) | SG149063A1 (enExample) |
| SI (1) | SI1663287T1 (enExample) |
| TN (1) | TNSN06071A1 (enExample) |
| TW (1) | TWI342782B (enExample) |
| WO (1) | WO2005021028A1 (enExample) |
| ZA (1) | ZA200601550B (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE40987E1 (en) | 1998-07-01 | 2009-11-17 | Debiopharm S.A. | Cyclosporin with improved activity profile |
| AU2004222306A1 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| GB0500020D0 (en) * | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
| JP2008506648A (ja) | 2004-07-14 | 2008-03-06 | ノバルティス アクチエンゲゼルシャフト | Ｃ型肝炎（ｈｃｖ）処置のためのシクロスポリンとペグ化インターフェロンの組合せ剤の使用 |
| WO2006039163A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| SI1802650T1 (sl) * | 2004-10-01 | 2012-03-30 | Scynexis Inc | Eter in tioeter substituirani ciklosporinski derivati za zdravljenje in preventivo pred infekcijami s hepatitisom c |
| PT1793844E (pt) | 2004-10-01 | 2011-03-10 | Debiopharm Sa | Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c |
| US7196161B2 (en) | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| ATE412005T1 (de) | 2004-11-22 | 2008-11-15 | Astellas Pharma Inc | Zyklosporinanalog |
| US7897565B2 (en) * | 2004-12-23 | 2011-03-01 | Novartis Ag | Compositions for HCV treatment |
| RU2007128098A (ru) * | 2004-12-23 | 2009-01-27 | Новартис АГ (CH) | Соединения для лечения инфекций, вызываемых вирусами семейства flaviviridae |
| RU2427372C2 (ru) * | 2005-06-17 | 2011-08-27 | Новартис Аг | Применение санглиферина для лечения вируса гепатита с |
| CN101316606B (zh) * | 2005-09-30 | 2015-05-27 | 西尼克斯公司 | 治疗和预防丙型肝炎感染的方法和药物组合物 |
| CA2623864C (en) * | 2005-09-30 | 2014-12-16 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection |
| CN105169369B (zh) * | 2005-09-30 | 2019-10-18 | 中美华世通生物医药科技（武汉）有限公司 | 治疗和预防丙型肝炎感染的方法和药物组合物 |
| PL1957518T3 (pl) * | 2005-10-26 | 2016-07-29 | Astellas Pharma Inc | Nowe cykliczne związki peptydowe |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| EP2023918B1 (en) | 2006-05-19 | 2011-03-23 | Scynexis, Inc. | Cyclosporins for the treatment and prevention of ocular disorders |
| KR101089112B1 (ko) * | 2006-06-02 | 2011-12-06 | 피씨 제스띠옹 에스.아.에스. | 활성 전자 관리 |
| SG175621A1 (en) * | 2006-10-12 | 2011-11-28 | Novartis Ag | Use of modified cyclosporins |
| US7576057B2 (en) | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
| RU2462262C2 (ru) * | 2007-01-04 | 2012-09-27 | Дебиофарм С А | Неиммуносупрессорный циклоспорин для лечения врожденной миопатии ульриха |
| KR20100017547A (ko) * | 2007-05-02 | 2010-02-16 | 아스텔라스세이야쿠 가부시키가이샤 | 신규 시클릭 펩티드 화합물 |
| US20110158908A1 (en) * | 2007-08-24 | 2011-06-30 | Sapporo Medical University | Cyclosporin a-binding protein |
| WO2009148615A1 (en) * | 2008-06-06 | 2009-12-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
| JP5820722B2 (ja) * | 2008-06-06 | 2015-11-24 | スシネキス インク | シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用 |
| AU2009276241A1 (en) * | 2008-07-30 | 2010-02-04 | Ciclofilin Pharmaceuticals Corp. | Nonimmunosuppressive cyclosporine analogue molecules |
| JP5625910B2 (ja) * | 2008-09-24 | 2014-11-19 | アステラス製薬株式会社 | ペプチド化合物およびその製造方法 |
| CA2741829A1 (en) * | 2008-11-06 | 2010-05-14 | Debio Recherche Pharmaceutique S.A. | Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
| CA2748389A1 (en) * | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| EP2391376A4 (en) | 2009-01-30 | 2012-08-01 | Enanta Pharm Inc | ANALOGUES OF CYCLOSPORIN FOR PREVENTING OR TREATING HEPATITIS C INFECTION |
| US8481483B2 (en) | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8367053B2 (en) | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8685917B2 (en) | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
| US8349312B2 (en) | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
| WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
| CN102869367A (zh) | 2009-12-09 | 2013-01-09 | 西尼克斯公司 | 新颖的环肽 |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| KR20140035305A (ko) | 2010-10-05 | 2014-03-21 | 노파르티스 아게 | C형 간염 바이러스 감염의 새로운 치료법 |
| CN105381450A (zh) | 2010-11-30 | 2016-03-09 | 诺华有限公司 | 丙型肝炎病毒感染的新疗法 |
| JO3337B1 (ar) | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| LT2651965T (lt) | 2010-12-15 | 2019-01-10 | Contravir Pharmaceuticals, Inc. | Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis |
| CN105749246A (zh) | 2011-03-31 | 2016-07-13 | 诺华股份有限公司 | 治疗丙肝病毒感染的阿拉泊韦 |
| RS53911B1 (sr) | 2011-04-01 | 2015-08-31 | Novartis Ag | Tretman u infekciji virusom hepatitis b zasebno ili u kombinaciji sa hepatitis delta virusom i bolesti jetre koje ih prate |
| KR20140011379A (ko) | 2011-04-13 | 2014-01-28 | 노파르티스 아게 | 알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료 |
| JP2014528947A (ja) | 2011-09-27 | 2014-10-30 | ノバルティス アーゲー | Ｃ型肝炎ウイルス感染症の治療のためのアリスポリビル |
| CA2872162A1 (en) | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmacokinetic modulation with alisporivir |
| CA2874548A1 (en) | 2012-06-01 | 2013-12-05 | Allergan, Inc. | Cyclosporin a analogs |
| US8906853B2 (en) | 2012-11-28 | 2014-12-09 | Enanta Pharmaceuticals, Inc. | [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection |
| WO2015008223A1 (en) | 2013-07-17 | 2015-01-22 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir and ribavirin |
| KR20160045136A (ko) | 2013-08-26 | 2016-04-26 | 이난타 파마슈티칼스, 인코포레이티드 | C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체 |
| WO2015136455A1 (en) | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
| WO2016073480A1 (en) | 2014-11-03 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Novel cyclosporin analogues for preventing or treating hepatitis c infection |
| WO2016112321A1 (en) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Cyclosporin derivatives wherein the mebmt sidechain has been cyclized |
| CN116367843A (zh) * | 2020-08-24 | 2023-06-30 | 纳诺莫里克斯有限公司 | 病毒抑制剂 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| DE69124459T3 (de) * | 1990-11-02 | 2001-05-31 | Novartis Ag, Basel | Zyklosporine |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US6174868B1 (en) * | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| WO1994008943A1 (fr) | 1992-10-21 | 1994-04-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose 2-amino-1,3-propanediol et immunosuppresseur |
| HUT75533A (en) | 1993-11-10 | 1997-05-28 | Schering Corp | Improved interferon polymer conjugates |
| ATE211726T1 (de) | 1994-08-22 | 2002-01-15 | Welfide Corp | Benzolderivate und deren medizinische verwendung |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| JP3786447B2 (ja) * | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| FR2757521B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2757520B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent |
| FR2757522B1 (fr) | 1996-12-24 | 1999-01-29 | Rhone Poulenc Rorer Sa | Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| USRE39072E1 (en) | 1997-04-04 | 2006-04-18 | Mitsubishi Pharma Corporation | 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| USRE40987E1 (en) * | 1998-07-01 | 2009-11-17 | Debiopharm S.A. | Cyclosporin with improved activity profile |
| EP1300405B1 (en) | 2000-07-13 | 2007-04-18 | Sankyo Company, Limited | Amino alcohol derivatives |
| EP1315735A4 (en) | 2000-08-31 | 2005-04-06 | Merck & Co Inc | Phosphate derivatives as immunoregulatory compounds |
| US20040033946A1 (en) * | 2000-10-19 | 2004-02-19 | Futoshi Shibasaki | Cell damage inhibitor |
| JP2002125683A (ja) * | 2000-10-27 | 2002-05-08 | Tokyoto Igaku Kenkyu Kiko | インターフェロンの有効性を予測する方法並びにそれに用いられるプライマー及びプローブ |
| MXPA03008755A (es) | 2001-03-26 | 2004-02-18 | Novartis Ag | Derivados de 2-amino-propanol. |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| CA2461212C (en) | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| DE60235900D1 (de) | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| ATE441654T1 (de) | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| AU2003202994B2 (en) | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| US20030213603A1 (en) | 2002-05-14 | 2003-11-20 | Fisher David B. | Dual use extension apparatus for a tool |
| AP2005003213A0 (en) | 2002-06-28 | 2005-03-31 | Univ Cagliari | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. |
| GB0313444D0 (en) | 2003-06-11 | 2003-07-16 | Midland Medical Technologies L | Modular dysplasia cup |
| GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| PT1793844E (pt) | 2004-10-01 | 2011-03-10 | Debiopharm Sa | Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c |
| US7897565B2 (en) | 2004-12-23 | 2011-03-01 | Novartis Ag | Compositions for HCV treatment |
-
2003
- 2003-09-03 GB GBGB0320638.0A patent/GB0320638D0/en not_active Ceased
-
2004
- 2004-09-02 AU AU2004268382A patent/AU2004268382A1/en not_active Abandoned
- 2004-09-02 PT PT04764762T patent/PT1663287E/pt unknown
- 2004-09-02 MX MXPA06002394A patent/MXPA06002394A/es active IP Right Grant
- 2004-09-02 RU RU2006110533/15A patent/RU2389501C2/ru not_active IP Right Cessation
- 2004-09-02 CN CNA2004800246044A patent/CN1842343A/zh active Pending
- 2004-09-02 US US10/570,097 patent/US7968518B2/en active Active
- 2004-09-02 DK DK04764762T patent/DK1663287T3/da active
- 2004-09-02 DE DE602004022061T patent/DE602004022061D1/de not_active Expired - Lifetime
- 2004-09-02 EP EP06125649.1A patent/EP1797892B1/en not_active Expired - Lifetime
- 2004-09-02 CA CA2537137A patent/CA2537137C/en not_active Expired - Fee Related
- 2004-09-02 KR KR1020067004342A patent/KR101116968B1/ko not_active Expired - Fee Related
- 2004-09-02 EP EP04764762A patent/EP1663287B1/en not_active Expired - Lifetime
- 2004-09-02 TW TW093126578A patent/TWI342782B/zh not_active IP Right Cessation
- 2004-09-02 ES ES04764762T patent/ES2328361T3/es not_active Expired - Lifetime
- 2004-09-02 JP JP2006525712A patent/JP4688806B2/ja not_active Expired - Fee Related
- 2004-09-02 WO PCT/EP2004/009804 patent/WO2005021028A1/en not_active Ceased
- 2004-09-02 NZ NZ545495A patent/NZ545495A/en not_active IP Right Cessation
- 2004-09-02 SG SG200809555-6A patent/SG149063A1/en unknown
- 2004-09-02 HR HR20090535T patent/HRP20090535T1/hr unknown
- 2004-09-02 BR BRPI0414062A patent/BRPI0414062B8/pt not_active IP Right Cessation
- 2004-09-02 SI SI200431200T patent/SI1663287T1/sl unknown
- 2004-09-02 PL PL04764762T patent/PL1663287T3/pl unknown
-
2006
- 2006-02-22 ZA ZA200601550A patent/ZA200601550B/en unknown
- 2006-02-23 IL IL173909A patent/IL173909A/en active IP Right Grant
- 2006-03-02 TN TNP2006000071A patent/TNSN06071A1/en unknown
- 2006-03-10 MA MA28865A patent/MA28032A1/fr unknown
- 2006-03-24 IS IS8371A patent/IS2917B/is unknown
- 2006-03-31 NO NO20061479A patent/NO20061479L/no not_active Application Discontinuation
-
2008
- 2008-07-09 AU AU2008203031A patent/AU2008203031B2/en not_active Ceased
-
2009
- 2009-09-16 CY CY20091100955T patent/CY1110506T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504260A5 (enExample) | ||
| JP2013529627A5 (enExample) | ||
| ATE473750T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion | |
| RU2010153688A (ru) | Режим дозирования телапревира | |
| JP2018512453A5 (enExample) | ||
| EA200700718A1 (ru) | Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения | |
| Chen et al. | Hepatitis C virus infection in Taiwan | |
| Abbas | Hepatitis D in pakistan | |
| Liaw | Viral hepatitis in Taiwan: status in the 1990s | |
| Müller | Pathogenicity of GBV‐C/HGV infection | |
| Pol et al. | Effectiveness and tolerance of interferon-α2b in the treatment of chronic hepatitis C in haemodialyis patients | |
| Abraham | Treatment for hepatitis C virus infection in India: promising times | |
| Sharifi et al. | Efficacy of locally manufactured sofosbuvir and daclatasvir (Sovodak) in combination with ribavirin in treating patients with chronic hepatitis c and cirrhosis in Iran–preliminary report | |
| Aderka et al. | Does tumor necrosis factor play a role in the pathogenesis of fulminant hepatitis? | |
| Lodi et al. | Hepatitis G virus: Relevance to oral health care | |
| Alavian | Hepatitis D is a forgotten problem in hemodialysis patients in the world | |
| Ibarra | Module XllTreatment of HBV–HCV coinfection | |
| Alavian | Optimal therapy for hepatitis C | |
| Fenoglio et al. | Cryoglobulinemia and Emerging Related | |
| Russello et al. | Recombinant interferon alpha therapy in elderly patients with chronic hepatitis C without cirrhosis | |
| Mahmood | Studying the possibility of confection of hepatitis C and hepatitis G viruses in Iraqi patients | |
| Elefsiniotis et al. | Immunogenicity of recombinant hepatitis B vaccine in treatment-na ve and treatment-experienced chronic hepatitis C patients: The effect of pegylated interferon plus ribavirin treatment | |
| Rothstein et al. | Interferon and other therapies for hepatitis B and hepatitis C infections | |
| Molloy et al. | Treatment of chronic hepatitis B and hepatitis C with... | |
| Iram et al. | HEPATITIS C VIRUS AMONG PATIENTS IN MARDAN REGION OF NORTHWEST PAKISTAN: MOLECULAR SIGNATURE AND RESPONSE TO SOFOSBUVIR AND DACLATASVIR THERAPY |